Biocryst researchers convicted
Former VP-Clinical Development Harry Snyder and his wife Renee Peugeot convicted March 23 by Birmingham, Ala. federal jury for falsifying test results on Biocryst's BCX-34, a drug which had been developed for psoriasis and T-cell lymphoma. The defendants were convicted on five counts, including making false statements to FDA in the statistical analysis on a Form 1571 regarding the effectiveness of BCX-34 and perpetrating mail fraud. Sentencing is scheduled for June 15. The maximum sentence is five years for each count. The U.S. attorney's office indicated it will not seek charges against the company. Biocryst discontinued development of BCX-34 in the fall of 1997
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth